In an interview with PharmaShots, Dr. Bob Deans, Chief Scientific Officer at Synthego shares insights on the wide availability of its new CRISPR-based platform, Eclipse. Synthego created the Eclipse platform to enhance disease modeling, drug target identification, and validation, and accelerate cell therapy manufacturing.
Shots:
Eclipse uses MLto apply experience from several hundred thousand genome edits across…
